Search
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes. … [A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on
Categories: Drugs Used in DiabetesOpium
go.drugbank.com/drugs/DB11130ApprovedIllicitin the category of isoquinolines. … Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: combinations of sulfonamides, Drugs Used in DiabetesEmapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.
Fluorine F-18
go.drugbank.com/drugs/DB13134InvestigationalFluorine-18 is under investigation in clinical trial NCT00870974 (A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions).
Fludeoxyglucose
go.drugbank.com/drugs/DB15107InvestigationalFludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalOn March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. … On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral
Categories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorImiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
International brands: Li Di, You CarePropranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigational[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904] … Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.
Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and ThiazidesSynonyms: 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol